Dr.Elizabeth Jacobs, MD/MAPP, Healthcare Research and Policy, https://www.drlizjacobsmd.com/
Dr. Liz is the Associate Chair for Research, Department of Internal Medicine at Dell Medical, and served as the VP for Research at MaineHealth, a not-for-profit family of high-quality providers and health care organizations in Maine recognized as one of the US's top integrated health care delivery networks. Dr. Liz previously served as Chief of Primary Care at Dell and prior to joining Dell Medical School, she was a professor of medicine and population health sciences and vice chair for health services research in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health.
Dr. Jacobs’ research interests include access to, and cultural specificity of, medical care delivered to patients, the impact of interpreter service interventions on the cost and quality of healthcare, health literacy, and numeracy, and the role that trust in healthcare plays in racial/ethnic disparities in health care. Her research has been supported by grants from the National Cancer Institute, the National Institute on Aging, The Robert Wood Johnson Foundation, The California Endowment, The Russell Sage Foundation, The Patient-Centered Outcomes Research Institute, and the Office of Minority Health.
She has served on the Office of Minority Health, Joint Commission, National Quality Forum, Patient-Centered Outcomes Research Institute, and AHRQ expert panels. She received the Chancellor's Community-Academic Partnership Award, 2017, University of Wisconsin System; Outstanding Investigator Award, 2017 School of Medicine and Public Health, University of Wisconsin, and Addis Costello Award, 2014, American College of Physicians Wisconsin Chapter. She attended medical school at the University of California at San Francisco and trained as a general internist at Brigham and Women’s Hospital in Boston. She completed a Robert Wood Johnson Clinical Scholars fellowship and a master’s in public policy at the University of Chicago.
Rashmi Kilam
Founder, Managing Director,
Bouin Capital
Rashmi is an early-stage purpose-driven advisor and investor focused on Human and Environmental Health. She brings in multidisciplinary experience and a diverse pool of social capital for 25 years across 20+ countries. Rashmi's career began with businesses in the Internet, mobile, SaaS, and VR. She has engaged with 2 investment banks, 3 global consulting firms, global family offices, and a dozen early-stage companies.
Distacom, which originally built Orange, J-Phone, StarTV, and the Hutchison group, owned Asia Pacific Capital. Rashmi first worked with their internet business and was the core team for their first B2B software acquisition that grew from 5-300 people from Tokyo to Johanessburg, now TechnoTree, Nasdaq Helsinki (TEM1V). Rashmi collaborated with Distacom's other investments, NASDAQ listed SUNDAY of Hong Kong (now PCCW) for catalyzing their GSM award, Blu SpA Italy (sold to Telecom Italia), and Spice Telecom in 2000. Rashmi built Bouin after her tenure as a Principal at a cross-border M&A advisory (acquired by Avasant) to collaborate with Edelweiss Capital (IPO in 2010), and three large IT & BPO companies including EvalueServe, Integreon, and Pipal.
Rashmi served on the Investment Advisory Committee of the Texas Women's Foundation, has been a venture mentor with the University of Texas, and supports Women in Healthcare, such as the HLTH Foundation. She was one of the early members of the Impact-only angel group, SWAN. Rashmi earned a Business degree and BSc in Biology and Chemistry from Delhi University in 1995. She speaks four languages fluently and is a Kashmiri Pandit, a Hindu minority community forcibly removed from their homeland.
Hemmie Chang
Life Sciences Chair, Foley Hoag
Recognized by Massachusetts Lawyers Weekly as Top Women and inducted into the LMG Life Sciences Hall of Fame, Hemmie is Chair of Foley Hoag's Licensing & Strategic Alliances Practice and Co-Chair of the Life Sciences Group. She brings in a strategic business perspective and legal acumen of two-plus decades of experience within the biopharmaceutical, medical device, gene and cell therapy, and genomics sectors. Hemmie has closed more than $16 billion in deals in recent years across diverse therapeutic areas with all leading pharma players globally. Her representations include Genevant Sciences in an LNP deal with Takeda, LegoChem Biosciences in several ADC deals with CStone, Pyxis, Iksuda and Takeda, Dicerna Pharmaceuticals (NASDAQ; DRNA) in multiple collaborations with Novo Nordisk, Eli Lilly, Alexion and Boehringer Ingelheim for GalXC RNAi therapeutics; Korean pharma Dong-A ST in a $525 million exclusive license opposite AbbVie for a Mer Tyrosine Kinase inhibitor; and Genomics Medicine Ireland in an AbbVie partnership with WuXi NexCODE Genomics for population genomics research in Ireland.
Hemmie is a frequent speaker on BIO and LES panels, teaches the "How to Create Value from Inventions" seminar as part of the Harvard Business School New Venture Competition, is an expert and panelist for Harvard's Office of Technology Development Experts-in-Residence program and serves as a mentor for MassBio, MassChallenge and North Shore InnoVentures companies. She advised the Asian American Legal Defense and Education Fund (AALDEF) and serves as a Director and Secretary for the South Cove Manor nursing home founded in Boston’s Chinatown and a Director of the Franklin Square House Foundation, which serves homeless women and children in the Greater Boston area.
Parwez Jugoo,
Barrister at Law,ex-Group Legal Counsel
Airtel & Zain
Parwez is ex-Group Legal Counsel for Airtel Africa that acquired assets of Zain Telecom in Africa who pursued law at the University of Mauritius and is a barrister of the Bar of Mauritius. He was a pupil of Lord Marks QC of the Inner Temple, England, and of Nicolas Sorensen of the Barreau d’Aix-en-Provence, France.
He is an expert in the telecommunications industry and has earned valuable experience for 30+ years, as a legal adviser to large telecom multi-nationals and in this capacity, he participated in numerous bids for telecoms licenses worldwide and was part of M&A teams during major transactions in those telecom groups. He was the ex-CEO of MADACOM, Madagascar, (now Airtel) where he helmed the company into a USD 100MN successful business prior to selling the company to Zain. A seasoned team leader, he has served with teams of PWC and he served was the ex-legal counsel with Celtel, and Zain (MTC group). He has acted as a legal advisor to the Distacom Group that owned Orange (now PCCW) in Hong Kong, Spice Telecom in India, and MADACOM S.A. in Madagascar. Parwez advised GSM license bids in Ivory Coast, DRC, Mayotte, Comoros, Anjouan, Mauritius, South Africa, and Lebanon. Until recently he was recently a team member at Benoit Chambers, a leading law firm in Mauritius.
He has an advanced Management course from London Business School. Parwez is excellent in English and French.
Vinod Sood,
Co-founder, MD, Hughes Systique Corp.
Mr Vinod Sood is Co-Founder and Managing Director at Hughes Systique Corporation (HSC), an Engineering R&D Solutions & Services company. He is also on the Board of Hughes Communications India. Prior to his current role, he was Head of Global Engineering and R&D at Hughes Software Systems (HSS) and served on its Board as well. HSC is a signatory to the UN Women and UN Global Compact’s Women’s Empowerment Principles (“WEPs”).
Vinod is a veteran of hi-tech software industry, during his career span of 36 years he has built high performance teams at premier R&D organizations in India. Vinod has an exceptional track record of building profitable and sustainable institutions from conceptualization to maturity. Before HSS, Vinod worked with C-DOT where he was part of the core team which designed India 1st Digital Switch. He is member of NASSCOM Engineering R&D Council and Chair of Northern Regional Council. Established in 1988, NASSCOM, a not-for-profit industry association, is the apex body for the 194 billion dollar IT BPM industry in India, an industry that had made a phenomenal contribution to India's GDP, exports, employment, infrastructure and global visibility.
Vinod is a member of Advisory Committee of the Institute of Informatics and Communications, University of Delhi, Shoolini University Solan, KR Mangalam University, BML Munjal University and Masters Union Business School Gurugram. Vinod is involved in guiding and mentoring young entrepreneurs and startups and is on the Advisory Boards of some of these startups. He is a TiE Charter member and is part of several CII, NASSCOM, and TiE juries to identify emerging startups and innovative product companies. An alumnus of PEC Chandigarh from where Vinod graduated with a Gold Medal.
Dr. Neil Campbell,
Board, Life Sciences Pennsylvania
MD, Mosaigen
A global C-level entrepreneurial executive with 25+ years of success building public and private businesses in science & technology sectors with a strong focus on the life sciences through the commercialization of over 290 products and services. Neil started his career with Abbot Labs, IGEN (Now Roche) and spent an executive career with private VC/PE international investment fund experience as a general partner and advisor and has advised HNWI, FOs, VC, and PE funds with board practice advisory services and helped build start-ups to Fortune 500 providing leadership in turnarounds, stagnant growth, emerging-growth, and developing country. Dr. Campbell runs Mosaigen, founded in 2004 as a global technology development corporation specializing in the life sciences, ICT, and Cleantech industries using a unique model "reverse startup" approach. This includes Nanotechnology & Material Sciences, Life Sciences (Pharma, Device, Diagnostics, Research, OTC/CPG), ICT (High-performance computing, Web 2.0, Machine Learning, Pattern Recognition/Dynamic Scaffolding, Virtualization platforms, Simulation, Physics Engines, and New Media), and lastly Clean/Green Tech (Solar, Wind, Smart Software, Materials, renewable Energy, non-food stock biofuels & ISBEs).
Neil has capital market experience from seed to IPO with over $420M directly raised and involved in roadshow teams for IPOs totaling > $1B. He is on the Investment Committee for Genomic Medicine Catalyst Investment Fund, UK. He is a scholar-practitioner, author, and speaker on innovation, entrepreneurship, and capital appreciation methods for science & technology commercialization. Neil received his doctorate from University of Liverpool, UK and MBA & MS from Webster.